News

The ongoing two-year study in methotrexate (MTX)-naïve patients with moderate-to-severe active RA, randomized to receive tofacitinib 5mg or 10mg twice-daily (BID) as monotherapy or MTX, met its primary

The OTC Retailing: U.S. Alternate Channel Analyses and Opportunities report said online sales saw the highest increase with a CAGR of 16.1% as the internet is increasingly becoming

Zetonna is also used to treat symptoms associated with seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR) in adults and adolescents 12 years of age and older.

Cabozantinib, a potent inhibitor of MET, VEGFR2 and RET, is at present being investigated across several tumor types. In preclinical studies, cabozantinib has demonstrated tumoricidal, antimetastatic and antiangiogenic

The submission of the application of the broad-spectrum anti-methicillin-resistant Staphylococcus aureus (MRSA) drug is supported by two international double-blind randomized controlled Phase III studies. Basilea chief executive officer

Following a positive opinion of Almirall’s new LAMA as a maintenance bronchodilator by the Committee for Medicinal Products for Human Use of the European Medicines Agency (CHMP) on

The comparative pharmacokinetic and bioavailability study enrolled 23 healthy adult volunteers and periodically measured circulating blood levels of cyclobenzaprine over six days after receiving study medication. The PK

Upon successful continued clinical development of PRO 140, CytoDyn will pay subsequent milestone payments to Progenics and based on net sales upon commercialization following final FDA approval royalty

Alnylam’s VaxiRNA platform uses RNAi technology for the enhanced manufacturing of vaccine products and applies siRNA for the silencing of specific genes that limit or prevent efficient manufacturing